Nanobiotix S.A. priced an oversubscribed global follow-on offering raising expected gross proceeds of about €85.0 million (approximately $98.6 million) before fees, with potential to reach about €87.8 million if the over-allotment option is fully exercised.
The deal comprises 225,373 ADSs at $38.98 each in the U.S., plus 1,959,289 ordinary shares at €33.60 and 345,099 pre-funded warrants at €33.57 in Europe and other markets. Each pre-funded warrant can be exercised in cash for one share at €0.03 until May 26, 2036.
The company plans to allocate between 50-60% of net proceeds to its Nanoprimer and other platforms, less than 10% to JNJ-1900 (NBTXR3), and 30-40% to general corporate purposes, and expects its cash resources plus this raise to fund operations into 2029. Illustrative tables show dilution for non-participating holders, with a 1% stake falling to about 0.95% on a fully diluted post-transaction basis and equity per share improving from -€1.75 to around -€1.66.
Nanobiotix S.A. reports that trading in its ordinary shares on the regulated market of Euronext Paris has resumed as of 3:30 p.m. Paris time / 9:30 a.m. New York time on May 21, 2026.
Trading had been halted earlier that day at the company’s request in connection with a previously announced global securities offering. This global offering includes a U.S. public offering of American Depositary Shares, each representing one ordinary share with a nominal value of €0.03, and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and certain other countries outside the United States and Canada.
Nanobiotix S.A. reports that trading of its ordinary shares on Euronext Paris is being temporarily halted at the company’s request. The halt is linked to a previously announced global equity financing that combines a U.S. public offering of American Depositary Shares with an international offering of ordinary shares and pre-funded warrants to qualified investors outside the United States and Canada.
The pause is intended to allow final allocation to investors and announcement of pricing for this global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, at about 3:30 p.m. Paris time, which corresponds to 9:30 a.m. in New York.